An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies
CADTH recommends that Jakavi should be reimbursed by public drug plans for the treatment of chronic graft-versus-host disease (cGvHD) if certain conditions are met.
Jakavi should only be covered to treat patients aged 12 years and older who did not show an adequate response to corticosteroids or other systemic treatments.
Jakavi should only be reimbursed if prescribed by specialists who have experience in the diagnosis and management of patients with cGvHD, and the cost of Jakavi is reduced.
Approximately 35% to 70% of patients who receive a stem cell transplant from a donor will experience cGvHD. Chronic GvHD occurs when the donor’s cells attack the transplant recipient's cells and body parts. Chronic GvHD usually starts 100 days or more after transplant and can last a few months or a lifetime.
There is currently no standard of care for patients with cGvHD who have an inadequate response to corticosteroids or other systemic treatments. Effective therapies with tolerable side effects that can improve health-related quality of life, reduce disease symptoms, and extend survival are needed.
Treatment with Jakavi is expected to cost approximately $63,786 per patient per year.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ruxolitinib be reimbursed for the treatment of chronic GvHD (cGvHD) in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies if the conditions listed in Table 1 are met.
One phase III, randomized, open-label trial (REACH 3, N = 329) demonstrated that treatment with ruxolitinib resulted in added clinical benefit in patients with steroid-refractory (SR) cGvHD. The REACH 3 trial demonstrated that compared with best available therapy (BAT) ruxolitinib was associated with statistically significant improvements in overall response rate (ORR) at cycle 7, day 1 (50.5% versus 26.3% in the BAT group; stratified odds ratio = 2.98, 95% CI, 1.62 to 5.48), failure-free survival (FFS) (stratified hazard ratio = 0.315, 95% CI, 0.205 to 0.486), and the modified Lee Symptom scale with a higher rate of responders in the ruxolitinib group up to cycle 7, day 1 (odds ratio = 2.62, 95% CI, 1.42 to 4.82). CDEC acknowledged the rarity of cGvHD and the significant unmet need for additional treatment options in this setting given the severe nature of this disease with substantial morbidity.
Patients expressed a need for treatments that can reduce disease symptoms, improve survival and quality of life, and decrease the severity of side effects. CDEC concluded that ruxolitinib met some important patient needs by reducing disease symptoms of cGvHD and providing an oral drug option with tolerable side effects that can be administered as an outpatient treatment. CDEC acknowledged that insufficient follow-up of survival outcomes led to uncertainty regarding long-term survival benefits of ruxolitinib (median FFS in the ruxolitinib group and median overall survival (OS) in both study groups was not reached). No definitive conclusion could be reached regarding the effects of ruxolitinib on health-related quality of life (HRQoL) due to a significant decline in the number of patients available to provide HRQoL assessments over time and the open-label design of the trial.
The cost-effectiveness of ruxolitinib is highly uncertain due to the sponsor’s use of a post-hoc analysis, which was used to populate the majority of model parameters, along with concerns regarding the model structure not adequately capturing the complexity of SR-cGvHD. As such, a base-case, cost-effectiveness estimate was unable to be determined for the treatment of patients aged 12 years and older with SR chronic GvHD who have inadequate response to corticosteroids or other systemic therapies. The committee considered exploratory analyses conducted by CADTH and determined that the incremental cost-effectiveness ratio (ICER) was likely closer to $1,062,977 per quality-adjusted life-year (QALY); therefore, ruxolitinib is not cost-effective at a $50,000 per QALY willingness-to-pay (WTP) threshold. A price reduction of at least 65% for ruxolitinib would be required for ruxolitinib to achieve an ICER of $50,000 per QALY compared with BAT.
Reimbursement Conditions and Reasons.
GvHD is a complication associated with allogeneic stem cell transplantation (alloSCT). GvHD is a multisystem disorder in which the donor-derived immune cells initiate an adverse immune reaction to the transplant recipient tissues, cells, and organs leading to tissue damage, organ failure, or death. cGvHD typically occurs 100 days or more after alloSCT and can last a few months or a lifetime. cGvHD occurs in 35% to 70% of patients who undergo alloSCT. Currently, there is no consensus on standard second-line therapies for patients with steroid-refractory cGvHD (SR-cGvHD). Available second-line options in Canada include extracorporeal photopheresis (ECP), mycophenolate mofetil (MMF), etanercept, low-dose methotrexate (MTX), infliximab, mechanistic target of rapamycin (mTOR) inhibitor (e.g., sirolimus), imatinib, rituximab, ibrutinib, low dose interleukin (IL)-2, pulsed cyclophosphamide, and rarely pentostatin. Available treatments for patients with SR-cGvHD have limited effectiveness and are associated with a number of side effects.
Ruxolitinib has been approved by Health Canada for the treatment of cGvHD in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies. Ruxolitinib is a Janus-associated kinase inhibitor. Ruxolitinib is available as 5 mg, 10 mg, 15 mg, and 20 mg tablets. The recommended dose is 10 mg administered orally twice daily. The Product Monograph states that tapering of ruxolitinib may be considered in patients with a response and after having discontinued corticosteroids. It is recommended to taper ruxolitinib by reducing the dose to 50% every 2 months; in the event that signs or symptoms of GvHD reoccur during or after the taper, re-escalation of ruxolitinib should be considered.
To make their recommendation, CDEC considered the following information:
Eight patient groups- the LC, LLSC, CLL Canada, Myeloma Canada, AAMAC, CMPNRF and the CML Network, MPN Canadian Research Foundation, and CTTC- co-created 1 joint patient input for this review. The input was based on an online survey and responses from a total of 68 participants were included in the patient input. Sixty patients reported having received a stem cell transplant (SCT), 6 patients reported not having received a SCT, and 2 patients did not provide an answer to this question. Out of the 60 patients that received a SCT, 49 patients reported having received an alloSCT. Fifty-three patients had experienced GvHD after their SCT. Data on the type of GvHD were available for 45 of the 53 patients with GvHD: 13% experienced acute GvHD (aGvHD), 24% experienced cGvHD, and 62% experienced both acute and chronic GvHD. Twenty patients reported receiving ruxolitinib treatment.
Respondents indicated that they had long-lasting GvHD symptoms (3 to 5 years for 26% of respondents and more than 5 years for 28% of respondents). To manage GvHD patient respondents reported requiring numerous medical consultations, hospital stays, and nights away from home. Respondents indicated a varying range of GvHD symptoms significantly impacting patients’ daily activities and causing detrimental effects on patients’ quality of life. Respondents highlighted problems with interruption of life goals and accomplishment (career, school), difficulty sleeping, impact on mental health (stress, anxiety, worry, and problems concentration), and financial impacts. Other commonly experienced symptoms indicated by respondents included burning and redness of the skin on the palms of the hands or soles of the feet, rashes that could spread over the entire body, blisters and peeling skin, skin problems such as dryness, rash, itching, peeling, darkening, hard texture and feeling tight, enlarged liver, liver tenderness, abnormal liver enzymes or liver failure, jaundice, dry eyes that may have a burning or gritty feeling, dry mouth with or without mouth ulcers, diarrhea, loss of appetite, stomach cramps, vomiting, weight loss, pain in muscles and joints, mobility issues and difficulties, infections, and difficulty breathing.
According to the patient input received, respondents expected new drugs or treatments to improve the following key outcomes: overall survival, GvHD symptoms, quality of life, and severity of side effects. Additionally, the ability to received treatment in the outpatient setting (rather than requiring an overnight hospital stay), having access to treatment locally (rather than requiring extensive amount of travel), treatment being covered by insurance or drug plans, and the treatment being recommended by health care professionals, were perceived to be very important by respondents. Respondents who had direct experience with ruxolitinib indicated that, overall, ruxolitinib was an effective treatment, improved their quality of life, had tolerable side effects, and was a treatment that they would take again if recommended by their physician, and that they would recommend it to other patients.
The clinical experts consulted by CADTH noted that there are currently no Health Canada authorized standard care regimens specific for patients with SR-cGvHD in Canada, except for ibrutinib which has been authorized since 2017 for the treatment of adult patients with SR-cGvHD but has not undergone review by CADTH and is not publicly reimbursed in Canada and available through private drug insurance only. According to the clinical experts consulted by CADTH available second-line options in Canada include ECP, MMF, etanercept, low-dose MTX, infliximab, mTOR inhibitor (e.g., sirolimus), imatinib, rituximab, ibrutinib, low dose IL-2, pulsed cyclophosphamide, and rarely pentostatin. There was consensus among the clinical experts that there is an unmet need for effective therapies with acceptable toxicity profile that improve HRQoL, reduce disease symptoms of cGvHD, enhance patient’s performance status, and improve overall survival. The need for a convenient oral route of administration was highlighted to achieve high adherence and reduce the need for hospital-based or ambulatory centre resource utilization. Ruxolitinib was stated to be used as add on to patients’ immunosuppressive regimen of corticosteroids ± CNI in patients aged 12 years and older with moderate or severe SR-cGvHD as per the REACH 3 trial. It was agreed that ruxolitinib, as a therapy for SR-cGvHD, would likely shift the current treatment paradigm. The clinical experts consulted by CADTH agreed that patients as selected per the inclusion/exclusion criteria of the REACH 3 trial should be eligible for ruxolitinib therapy. The clinical experts identified the following potential subgroups as being most in need of ruxolitinib therapy: patients with glucocorticoid refractory as opposed to glucocorticoid dependent cGvHD and patients with bronchiolitis obliterans. Patient subgroups who would potentially benefit the least from ruxolitinib may include patients with isolated lichenoid cGvHD, who may preferentially be treated with ECP or subcutaneous low dose IL-2 rather than ruxolitinib. Patients with strictly autoimmune cGvHD manifestations such as immune thrombocytopenia (as well as immune hemolytic anemia, immune glomerulonephritis, and myasthenia gravis) may preferentially be treated with rituximab. The clinical experts consulted by CADTH felt that it would be reasonable to generalize the results from the REACH 3 trial to patients who received 2 or more systemic treatments for cGvHD in addition to corticosteroids ± CNI as well as patients with Eastern Cooperative Oncology Group (ECOG) of 3 or Karnofsky Performance Status or Lansky Performance Status of less than 60% if performance status is related to cGvHD, and its symptoms. Furthermore, it was agreed that it would be reasonable to leave it up to the discretion of the treating physician to apply some flexibility in terms of using ruxolitinib in patients with overlap syndrome and patients with mild cGvHD.
In the opinion of the clinical experts consulted by CADTH, an accurate assessment of response in cGvHD is based on the National Institute of Health (NIH) consensus criteria, as was used in the REACH 3 trial. Response to treatment is usually assessed every 2 to 4 weeks, depending on the severity of cGvHD. Weekly assessment may be required initially. The clinical experts indicated that the most clinically meaningful responses to treatment include overall response (complete or partial response), improvements in HRQoL and performance status, reduction in cGvHD symptoms (frequency/ severity), stability of disease (no deterioration), and improved overall survival as well as the ability to reduce the dose of immunosuppression/ corticosteroids without flare of cGvHD signs and symptoms and having to start another agent for cGvHD.
In the opinion of the clinical experts consulted by CADTH, treatment with ruxolitinib should be discontinued if a patient experiences cGvHD disease progression, relapse of underlying hematologic malignancy, or experiences intolerable toxicity (e.g., anemia, thrombocytopenia or neurologic toxicity that cannot be managed with drug interruption and or dose reduction). Tapering ruxolitinib in responders may be considered after 24 weeks of therapy.
Two clinician group inputs were provided, 1 from CTTC (based on input from 8 clinicians) and 1 from Ontario Health CCO Complex Malignant Hematology (based on input from 2 clinicians). The views of the clinician groups were overall consistent with the clinical experts consulted by CADTH indicating that based on the evidence from the REACH 3 trial it was anticipated that ruxolitinib would become the dominant first-line therapy for SR-cGvHD. The outcomes assessed in the REACH 3 trial were judged to be applicable to Canadian clinical practice and reflective of clinically meaningful responses. It was noted by both inputs that ruxolitinib is not considered to be as immunosuppressive as other available therapies. The clinicians from Ontario Health CCO noted the drawbacks of currently available therapies, such as the IV administration, which requires patients to be at the hospital, side effects and broad immune suppression, and the high price and deliver costs of treatments. It was highlighted by the input from CTTC that a Health Canada–approved and provincially funded therapy for SR-cGvHD would be an important step forward in the present target setting with existing therapies offering low response rates and high rates of toxicity. According to the input from CTTC the experience with ruxolitinib (accessible via compassionate access program) and real-world effectiveness appears similar to that observed in the REACH 3 trial with low rates of toxicity.
Input was obtained from the drug programs that participate in the CADTH reimbursement review process. The following were identified as key factors that could potentially impact the implementation of a CADTH recommendation for ruxolitinib:
The clinical experts consulted by CADTH provided advice on the potential implementation issues raised by the drug programs.
Responses to Questions from the Drug Programs.
The REACH 3 trial is a an ongoing, international, multi-centre, open-label, randomized phase III trial of ruxolitinib (10 mg, oral twice daily) compared with investigator’s choice of BAT in patients aged 12 years and older with moderate or severe SR-cGvHD. Patients continued to receive their systemic immunosuppressive regimen of corticosteroids ± CNI per standard of care. A total of 329 patients were randomized in a 1:1 ratio to receive ruxolitinib or BAT. Randomization was stratified by cGvHD severity per 2014 NIH consensus criteria (Jagasia et al., 2015) (moderate versus severe). The primary outcome was ORR on cycle 7, day 1 and key secondary outcomes included FFS and the modified Lee Symptom Scale. Additional secondary outcomes were ORR at cycle 4, day 1, HRQoL, symptom severity, duration of response (DoR), best overall response (BOR), OS, non-relapse mortality, incidence of malignancy relapse or progression (MR), steroid dosing, resource utilization, and safety.
The REACH 3 trial enrolled patients, at least 12 years of age, who had undergone alloSCT, had evidence of myeloid and platelet engraftment (area under the curve [ANC] > 1,000/mm3 and platelet count > 25,000/mm3), and were diagnosed with moderate or severe cGvHD, which was determined to be corticosteroid refractory as per NIH consensus criteria (Martin et al. 2015). Patients with 2 or more systemic treatments for cGvHD in addition to corticosteroids ± CNI, impaired renal, GI function, or liver disease associated or non-associated with GvHD were excluded. The mean ages for the ruxolitinib and BAT groups, respectively, were 45.9 (standard deviation [SD]: 15.68) and 47.2 (SD: 16.17). The ruxolitinib group had a lower proportion of female patients compared to BAT (33.0% versus 43.9%), patients meeting the corticosteroid refractory ‘A’ criteria (37.6% versus 44.5%), and patients who only received steroid as prior systemic cGvHD/ SR/cGvHD therapy (42.4% versus 49.4%); and a higher proportion of patient with prior aGvHD of grade 2 (32.1% versus 26.2%), and patients meeting the corticosteroid refractory ‘B’ criteria (35.2% versus 25.6%). The majority of patients (ruxolitinib versus BAT) had severe SR-cGvHD (58% versus 54.9%), met corticosteroid refractory ‘A’ (37.6% versus 44.5%) or ‘B’ (35.2% versus 25.6%) criteria, and most patients had received either only steroid (42.4% versus 49.4%) or steroid plus CNI (41.2% versus 42.1%) as prior systemic cGvHD/ SR-cGvHD therapy. Malignant leukemia/ myelodysplastic syndrome (MDS) was the most common underlying disease (ruxolitinib versus BAT: 73.3% versus 74.4%) and the mean time of transplant to cGvHD diagnosis as well as the mean time from initial diagnosis to randomization were similar across groups (mean days: 247.0 versus 230.0 and mean years: 3.90 versus 3.52, respectively).
This CADTH review is based on the data cut-off date of May 8, 2020. Final study results are expected to occur after the completion of the study (estimated completion date is between the third and fourth quarter of 2022). A fixed sequence hierarchical testing procedure was applied for the primary and the 2 key secondary end points, which included the interim analysis (when 196 patients [60% of the targeted 324 patients] completed cycle 7, day 1 visit or discontinued earlier; July 9, 2019 data cut-off date) and the primary analysis (all 329 patients completed cycle 7, day 1 visit or discontinued earlier; May 8, 2020 data cut-off date).
As of the interim analysis (July 9, 2019, data cut-off date) the median FFS was not reached (95% CI, 11.9 to NE) for in the ruxolitinib group and was 5.6 (4.5 to 5.8) months in the BAT group with a stratified hazard ratio (HR) of 0.315 (95% CI, 0.205 to 0.486) in favour of the ruxolitinib group. As of the primary analysis (May 8, 2020 data cut-off date), median FFS was not reached (95% confidence interval [CI], 18.6 to NE) for the ruxolitinib group and was 5.7 (95% CI, 5.6 to 6.5) months in the BAT group with a stratified HR of 0.370 (95% CI, 0.268 to 0.510) in favour of the ruxolitinib group. FFS was not formally tested at the primary analyses, given that results reached statistical significance at the interim analysis.
As of the interim analysis (July 9, 2019 data cut-off date), the REACH 3 trial met its primary objective. The proportion of patients who achieved an overall response at Cycle 7 Day 1 was 50.5% (n = 49) (95% CI, 40.2 to 60.8) in the ruxolitinib group and 26.3% (n = 26) (95% CI, 17.9 to 36.1) in the BAT group with a stratified odds ratio of 2.98 (95% CI, 1.62 to 5.48). The proportion of patients with CR and PR was 8.2% (n = 11) and 42.3% (n = 71), respectively, in the ruxolitinib group and 3.0% (n = 5) and 23.2% (n = 37), respectively, in the BAT group. As of the primary analysis (May 8, 2020) the ORR at Cycle 7 Day 1 was achieved by 49.7% (n = 82) (95% CI, 41.8 to 57.6) of patients in the ruxolitinib group and 25.6% (n = 42) (95% CI, 19.1 to 33.0) of patients in the BAT group with a stratified odds ratio of 2.99 (95% CI, 1.86 to 4.80). ORR at Cycle 7 Day 1 was not formally tested at the primary analyses, given that results reached statistical significance at the interim analysis. The proportion of patients with CR and PR was 6.7% (n = 11) and 43.0% (n = 71), respectively, in the ruxolitinib group and 3.0% (n = 5) and 22.6% (n = 37), respectively, in the BAT group. The ORR cycle 1, day 1 supportive analysis using the per protocol analysis set showed consistent results with the ORR results for the full analysis set.
At the primary analysis results for the modified Lee Symptom Scale suggested that the rate of responders (responders included patients achieving an improvement of at least 7 points on the total symptom score [TSS] from baseline) up to cycle 7, day 1 was higher in the ruxolitinib group (24.2% [95% CI, 17.9 to 31.5]) compared to the BAT group (11% [95% CI, 6.6 to 16.8]) with an odds ratio of 2.62 (95% CI, 1.42 to 4. 82). The improvement of the TSS response was formally tested at the primary analysis as the result at the interim analysis did not reject the null hypothesis.
At the May 8, 2020 date cut-off date, the proportion of patients that had achieved BOR (CR or PR at any time point up to and including Cycle 7 Day 1 and before the start of change/addition of systemic therapy for cGvHD) was 76.4% (95% CI, 69.1 to 82.6) in the ruxolitinib group and 60.4% (95% CI, 52.4 to 67.9) in the BAT group, with an odds ratio of 2.17 (95% CI, 1.34 to 3.52). Among the patients who achieved a BOR, median DoR was not reached (95% CI, 20.2 to NE) in the ruxolitinib group and was 6.2 (95% CI, 4.7 to 13.1) months in the BAT group.
As of the May 8, 2020 data cut-off date, 58 death events occurred across both study groups. The median duration of follow up for OS was 57.3 weeks for all patients and for each treatment group was: 56.6 weeks in the ruxolitinib group and 57.9 weeks in the BAT group. Median OS was not reached (95% CI, NE to NE) in both study groups with a stratified HR of 1.86 (95% CI, 0.648 to 1.820).
During the time interval of Day 166 to Day 168 (end of cycle 6), a similar number of patients in both study groups achieved a ≥ 50% reduction of corticosteroid dose (body weight-normalized) from baseline (ruxolitinib group: 84 patients out of 118, 71.2%; BAT group: 80 patients out of 115, 69.6%). The reduction of steroid dose in the ruxolitinib group was slightly (but consistently) higher compared to the BAT group. The number of patients with no steroids during the time interval of Day 155 to Day 168 was 37 (31.4%) in the ruxolitinib group and 32 (27.8%) in the BAT group.12
Up to cycle 7, day 1 the percentage of patients reporting at least 1 TEAE was 97.6% in the ruxolitinib group and 91.8% in the BAT group. The most commonly reported TEAEs in the ruxolitinib group (ruxolitinib versus BAT) were anemia (29.1% versus 12.7%), pyrexia (15.8% versus 9.5%), alanine aminotransferase increased (15.2% versus 4.4%), hypertension (15.8% versus 12.7%), and blood creatine increased (13.9% versus 4.4%).12 The most commonly reported TEAEs in the BAT group (ruxolitinib versus BAT) were diarrhea (10.3% versus 13.3%), anemia (29.1% versus 12.7%), hypertension (15.8% versus 12.7%), pneumonia (10.9% versus 12.7%), and nausea (9.1% versus 10.1%). The percentages of patients reporting grade 3 or higher TEAEs up to cycle 7, day 1 was similar across both study groups (57.0% of patients in the ruxolitinib group and 57.6% in the BAT group). The most commonly reported grade 3 or higher TEAE (ruxolitinib versus BAT) was anemia in the ruxolitinib group (12.7% versus 7.6%) and pneumonia in the BAT group (8.5% versus 9.5%). Other commonly reported grade 3 or greater TEAEs occurring across both treatment groups up to cycle 7, day 1 (ruxolitinib versus BAT) included neutropenia (8.5% versus 3.8%), thrombocytopenia (10.3% versus 5.7%), gamma-glutamyl transferase increased (6.7% versus 1.9%), and hypertension (4.8% versus 7.0%).
Up to cycle 7, day 1, the percentage of patients reporting serious TEAEs was 33.3% in the ruxolitinib group and 36.7% in the BAT group. The most commonly reported serious TEAE in both study groups was pneumonia, occurring in 7.9% of patients in the ruxolitinib group and 8.2% of patients in the BAT group. Other commonly reported serious TEAEs occurring across both treatment groups (ruxolitinib versus BAT) included pyrexia (4.8% versus 1.9%), febrile neutropenia (1.8% versus 1.3%), pulmonary embolism (1.2% versus 1.9%), and acute kidney injury (1.2% versus 1.9%).
Up to cycle 7, day 1, the percentage of patients discontinuing study treatment due to TEAEs was 16.4% in the ruxolitinib group and 7.0% in the BAT group. The most commonly reported TEAE leading to treatment discontinuation in both study groups was pneumonia (4.8% in the ruxolitinib group and 1.3% in the BAT group), followed by anemia (0.6% in the ruxolitinib group and 0.6% in the BAT group). Pneumothorax occurred in 1.2% of patients in the ruxolitinib group and in no patients in the BAT group.
Up to cycle 7, day 1, the numbers of patients experiencing on-treatment deaths were 13 (7.9%) and 9 (5.7%) in the ruxolitinib and BAT groups, respectively. The most common cause of on-treatment death up to Cycle 7 Day 1 was the study indication (cGvHD and/or complications attributed to treatment for cGvHD) in 12 (7.3%) and 6 (3.8%) patients in the ruxolitinib and BAT groups, respectively. One patient in the ruxolitinib group died more than 30 days after the last dose due to general physical health deterioration. One patient each died from pneumonia, sepsis, and systemic infection in the BAT group.
Up to cycle 7, day 1, the most commonly reported infections in the ruxolitinib and BAT groups were infections excluding tuberculosis (62.4% and 58.2%, respectively), other infections (48.5% and 47.5%, respectively), pneumonia (19.4% and 17.1%, respectively), and opportunistic infections (11.5% and 12.0%, respectively).
Up to cycle 7, day 1, the number of patients reporting lipid abnormality events of any grade were 31 (18.8%) and 23 (14.6%) patients in the ruxolitinib and BAT groups, respectively. The most commonly reported lipid abnormalities in the ruxolitinib and BAT groups, respectively, were hypertriglyceridemia (9.7% and 8.2%), blood cholesterol increased (7.3% and 4.4%), hypercholesterolaemia (5.5% and 1.3%) and hyperlipidemia (2.4% and 2.5%).
Up to cycle 7, day 1, the number of patients reporting renal and urinary disorders of any grade 16 (9.7%) and 17 (10.8%) patients in the ruxolitinib and BAT groups, respectively. The most commonly reported renal and urinary disorders in the ruxolitinib and BAT groups were acute kidney injury (2.4% and 3.8%, respectively), renal failure (1.2% and 1.3%, respectively), hematuria (1.2% and 1.9%, respectively), and proteinuria (0.6% and 1.3%, respectively).
Up to cycle 7, day 1, the most commonly reported cytopenia events of any grade in the ruxolitinib and BAT groups were erythropenia (29.7% and 12.7%, respectively), leukopenia (18.8% and 13.9%, respectively), thrombocytopenia (21.2% and 14.6%, respectively), and other cytopenias (1.2% and 1.3%, respectively).
Up to cycle 7, day 1, the most commonly reported bleeding events of any grade in the ruxolitinib and BAT groups were hemorrhage (11.5% and 14.6%, respectively), hemorrhage events (6.7% and 10.1%, respectively), bruising (4.2% and 2.5%, respectively), and GI bleeding (1.2% and 3.2%, respectively).
The REACH 3 trial had an open-label design whereby the investigator and the study participants were aware of their treatment status, which increased the risk of detection and performance bias. This had the potential to bias results and outcomes in favour of ruxolitinib if the assessor (investigator or patient) believed the study drug is likely to provide a benefit. Subjective outcomes (i.e., adverse outcomes and patient-reported outcomes [e.g., modified Lee Symptom scale]) may be particular at risk of bias due to the open-label design. Furthermore, the underlying complexity of cGvHD has been acknowledged as a key challenge for the design and analysis of clinical trials in the current target setting and may contribute to subjective inter-physician variability in response assessments. To mitigate the impact of this bias, the investigators used standardized criteria (i.e., cGvHD disease evaluation and response assessment criteria for all organs were done according to NIH consensus criteria [Lee 2015] to evaluate responses). Patients in the BAT group who did not achieve responses were allowed to add or initiate a new systemic therapy in the BAT group up to cycle 7, day 1 without having to discontinue initial study treatment; however, patients in the ruxolitinib group were discontinued from treatment, if they changed or added a systemic therapy. This design feature may have biased the reporting of adverse events (AEs) leading to treatment discontinuation against the ruxolitinib group. The clinical experts consulted by CADTH noted that changing or initiating new systemic cGvHD therapies is reflective of clinical practice. It was felt by the clinical experts, that changes to the BAT treatment up the cycle 7, day 1 were unlikely to impact OS results, given the similar efficacy and similar responses achieved with various systemic therapies. The modified Lee Symptom scale scores were measured up to cycle 7, day 1 (cycle length = 28 days), which may not represent an accurate picture of patients’ experiences with ruxolitinib for a prolonged period of time. However, the assessment time frame coincided with the assessment of the primary outcome, ORR at cycle 7, day 1, and the clinical experts consulted by CADTH agreed that changes in symptom severity would be apparent within the first 6 Cycles after starting treatment. Given several important limitations including the non-inferential analyses, the significant decline in patients available to provide assessment over time, and the open-label design of the trial, the ability of interpret the results for the European Quality of Life 5-Five Dimensions 5-Levels (EQ-5D-5L) and The Functional Assessment of Cancer Therapy (FACT)-Bone Marrow Transplantation scores is limited.
It was noted that few patients in the trial were younger than 18 years. The clinical experts supported generalizing the study results to adolescents less than 18 years old, as these patients are managed similarly as adults in clinical practice, the safety profile of ruxolitinib in these patients was acceptable and similar to the overall safety set, and there is no biologic rational to assume that outcomes of ruxolitinib would be different between adult and adolescent patients with SR-cGvHD. It was agreed by the clinical experts that the NIH consensus criteria used in the trial for cGvHD disease and response assessment as well as the tarping schedule for treatments applied in the trial were overall reflective of Canadian clinical practice. The proportions of patients with cGvHD disease staging of mild, moderate, and severe as well as the proportions of patients meeting the SR-cGvHD criteria (‘A’ versus ‘B’ versus ‘C’) were reflective of patients seen in clinical practice.
No indirect treatment comparisons were included in the sponsor’s submission to CADTH or identified in the literature search.
The other relevant evidence section included:
The article by Moiseev et al. (2020) was a prospective, single-centre, open-label study in Russia that included 75 patients with either acute (N = 32) or chronic (N = 43) SR-GvHD. The study sample included both adults and children, with half of the sample comprised of children (53% in the acute and 39% in the chronic GvHD groups). The median ages in the acute and chronic GvHD groups were 17 years (range: 1 to 67) and 21 years (range:2 to 62), respectively. Study participants received ruxolitinib at a starting dose of 10 mg twice a day for adults, 10 mg twice a day for children weighing more than 40 kg, and 0.15 mg/kg twice a day for children weighing less than 40 kg. Previous treatments were continued if the attending physician considered it necessary. Ruxolitinib was stopped if there were signs of GvHD progression. The primary end point was ORR. ORR for acute and chronic GvHD was assessed based on the joint statement criteria by Martin et al (2009) and the NIH criteria by Lee et al. (2015), respectively. The secondary end points included OS, toxicity, relapse, and infection complications.
The ORR was 75% (95% CI, 57 to 89) in the aGvHD and 81% (95% CI, 67 to 92) in the cGvHD group. The OS was 59% (95% CI, 49 to 74) in the aGvHD and 85% (95% CI, 70 to 93) in the cGvHD group. In patients with aGvHD and cGvHD, there were no significant differences between adults and children in any of the outcomes, including ORR (aGvHD: P = 0.31; cGvHD: P = 0.35) and survival (aGvHD: P = 0.44; cGvHD: P = 0.12).
The most common AE was hematological toxicity, with 79% and 44% of grade III to IV neutropenia occurring in the acute and chronic GvHD groups, respectively. There were no significant differences in toxicity between adults and children.
Given the single-arm observational design, interpretation of the study results is limited. Due to the lack of a comparator group and blinding, it is difficult to determine the effectiveness of the treatment on the study outcomes. Given the relatively small sample size of cGvHD patients (N = 43), the generalizability of these results may be limited. Moreover, as this trial was conducted in Russia, there may be limitations generalizing these findings to the Canadian context.
In the REACH III trial, the number of patients aged 12 to 18 years represented a small proportion of the study sample (3.6%). In the study by Moiseev et al., approximately 50% of the study sample included children younger than18 years of age. Hence, this additional study supplements the evidence for ruxolitinib in patients younger than 18 years of age.
Several post-hoc analyses of the REACH 3 trial were conducted, and the results were applied to the submitted pharmacoeconomic model. High-level summaries of the methods and results of the post-hoc analyses were provided by the sponsor. The post-hoc analyses included OS by response, DOR by ORR, duration of treatment form randomization, duration of treatment by response at and from cycle 7, day 1, resource use by study group and response at cycle 7, day 1, and weekly dosing. The CADTH review team was unable to conduct a rigorous evaluation of the conduct and reporting of the post-hoc analyses as only a high-level summary of methods was provided by the sponsor. Overall, the CADTH Methods Team concluded that the results from post-hoc analyses are considered exploratory and hypotheses generating only. Due to the lack of formal inferential statistical testing, the CADTH review team’s ability to interpret results of such analyses is significantly limited.
Cost and Cost-Effectiveness.
CADTH identified the following key limitations with the sponsor’s analysis: First, there is uncertainty in the estimated population size because the sponsor’s approach relies heavily on clinical expert opinion. Further, the sponsor’s assumed proportion of patients eligible for public coverage underestimated the market size and budget impact. Second, there is uncertainty in the market share of ruxolitinib and its comparators. Finally, there is uncertainty in dosing, treatment duration, and the treatment cost of comparators.
CADTH reanalysis included: adopting the perspective of the public drug payer, revising market shares of comparators, assuming a higher market share and rapid uptake of ruxolitinib, and aligning dosing of rituximab, ibrutinib, imatinib and ECP with the product monographs and the published literature.
Although the sponsor suggested ruxolitinib would be associated with a budget impact of $10,440,825 over the 3-year time horizon, based on CADTH reanalysis, the budget impact to the public drug plans of introducing ruxolitinib is expected to be $10,350,040 in year 1, $7,771,389 in year 2, and $5,805,567 in year 3, for a 3-year total of $23,926,995. The estimated budget impact is sensitive to the proportion of existing patients with SR-cGvHD among alloSCT recipients.
Dr. James Silvius (Chair), Dr. Sally Bean, Mr. Dan Dunsky, Dr. Alun Edwards, Mr. Bob Gagne, Dr. Ran Goldman, Dr. Allan Grill, Dr. Christine Leong, Dr. Kerry Mansell, Dr. Alicia McCallum, Dr. Srinivas Murthy, Ms. Heather Neville, Dr. Danyaal Raza, Dr. Emily Reynen, and Dr. Peter Zed.
Meeting date: March 23, 2022
Regrets: Of the expert committee members, 2 did not attend.
Conflicts of interest: None
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Redactions: Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies
Sponsor: Novartis Pharmaceutical Canada Inc.
Final recommendation: Reimburse with conditions
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
